Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the goals of therapy in multiclass-experienced patients and strategies for optimal use of new agents to regain virologic control
- Review recent clinical trial data on the use of approved and investigational antiretrovirals in multiclass-experienced patients
- Discuss clinical strategies for maintaining a patient’s immunologic and clinical status while awaiting new, active agents to construct a suppressive regimen
Topics covered include:
- Introduction
- Goals and Strategies for Treatment-Experienced Patients
- Initial Assessment of Treatment Failure
- Selecting a Background Regimen in Highly Experienced Patients
- Strategies for Using New Agents to Regain Control of HIV in Treatment-Experienced Patients
- Enfuvirtide
- Tipranavir
- Investigational Second-Generation Agents: Darunavir (TMC114)
- Investigational Second-Generation Agents: Etravirine (TMC125)
- Investigational Second-Generation Agents: Dexelvucitabine (D-d4FC)
- Investigational Agents in New Drug Classes: Novel Entry Inhibitors
- Investigational Agents in New Drug Classes: Integrase and Maturation Inhibitors
- Options if New Drugs Are Not Available
- Options if New Drugs Are Not Available: Mega-HAART and Dual-Boosted PI Therapy
- Options if New Drugs Are Not Available: Use a Nonsuppressive Holding Regimen
- Options if New Drugs Are Not Available: Treatment Interruption
- Summary and Conclusions